Incidence, management, and course of cancer in patients with inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 9, Issue 4, 2015, Pages 326-333

  Algaba, Alicia ^a   Guerra, Iván ^a   Marín Jiménez, Ignacio ^b   Quintanilla, Elvira ^c   López Serrano, Pilar ^d   García Sánchez, María Concepción ^e   Casis, Begoña ^f   Taxonera, Carlos ^g   Moral, Ignacio ^h   Chaparro, María ⁱ   Martín Rodríguez, Daniel ^j   Martín Arranz, María Dolores ^k   Manceñido, Noemí ^l   Menchén, Luis ^b   López Sanromán, Antonio ^e   Castaño, Ángel ^a   Bermejo, Fernando ^a  

^a HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL SEVERO OCHOA   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^j HOSPITAL INFANTA CRISTINA   (Spain)

^k HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^l HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

more..

Author keywords

Anti TNF drugs; Cancer risk; Inflammatory bowel disease; Thiopurines

Indexed keywords

MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER REGRESSION; CANCER RISK; CANCER THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; NON MELANOMA SKIN CANCER; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SMALL INTESTINE CANCER; ULCERATIVE COLITIS; CLINICAL TRIAL; COMPLICATION; DISEASE MANAGEMENT; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MULTICENTER STUDY; NEOPLASMS; PROCEDURES; SPAIN; TIME;

ANTI-INFLAMMATORY AGENTS; DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPAIN; TIME FACTORS;

EID: 84953343630     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv032     Document Type: Article

References (39)

1. Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005;100:2724-9
2. Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 2013;145:166-75
3. Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol 2014;12:265-73
4. Katsanos KH, Tatsioni A, Pedersen N, et al. Cancer in inflammatory bowel disease 15 years after diagnosis in a population-based European Collaborative follow-up study. J Crohns Colitis 2011;5:430-42
5. Algaba A, Guerra I, Castaño A, et al. Risk of cancer, with special reference to extra-intestinal malignancies, in patients with inflammatory bowel disease. World J Gastroenterol 2013;19:9359-65
6. Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 2010;105:1480-7
7. von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum 2007;50:839-55
8. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91:854-62
9. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-8
10. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25
11. Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry. Am J Gastroenterol 2014;109:212-23
12. Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with metaanalysis: malignancies with anti-tumour necrosis factor-a therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2014;39:447-58
13. Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-a antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 2014;18;31:2406-13
14. Beaugerie L. Use of immunosuppressants and biologicals in patients with previous cancer. Dig Dis 2013;31:254-9
15. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2-6; discussion 16-9
16. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012;143:390-9
17. Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011;141:1612-20
18. Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 2014;109:163-9
19. Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 2012;27:385-9
20. Perrett CM, Walker SL, O'Donovan P, et al. Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. Br J Dermatol 2008;159:198-204
21. Magro F, Peyrin-Biroulet L, Sokol H, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop [III]. J Crohns Colitis 2014;8:31-44
22. Long MD, Kappelman MD, Pipkin CA. Nonmelanoma skin cancer in inflammatory bowel disease: a review. Inflamm Bowel Dis 2011;17:1423-7
23. Williams GM. Antitumor necrosis factor-alpha therapy and potential cancer inhibition. Eur J Cancer Prev 2008;17:169-77
24. Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and metaanalysis. Clin Gastroenterol Hepatol 2014;12:210-8
25. Peyrin-Biroulet L, Chevaux JB, Bouvier AM, et al. Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased. Am J Gastroenterol 2012;107:1443-4
26. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005;54:617-22
27. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 2014 May 28. pii: S1542-3565[14]00767-8
28. Osterman M, Sandborn W, Colombel JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology 2014;146:941-9
29. SEER. Non-Hodgkin lymphoma statistics.www.cdc.gov/cancer/hematologic /lymphoma/statistics Accessed 6 November, 2007
30. Williamson JM, Williamson RC. Small bowel tumors: pathology and management. J Med Assoc Thai 2014;97:126-37
31. Higashi D, Futami K, Kojima D, et al. Cancer of the small intestine in patients with Crohn's disease. Anticancer Res 2013;33:2977-80
32. Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013;19:789-99
33. Jess T, Simonsen J, Jørgensen KT. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012;143:375-81
34. Castaño-Milla C, Chaparro M, Gisbert JP. Systematic review with metaanalysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther 2014;39:645-59
35. van Schaik FD, van Oijen MG, Smeets HM, van der Heijden GJ, Siersema PD, Olderburg B. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012;61:235-40
36. Baars JE, Looman CW, Steyerberg EW, et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol 2011;106:319-28
37. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007;67:1167-98
38. Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 2004;104:822-8
39. Dixon WG, Watson KD, Lunt M, et al. Influence of antitumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res [Hoboken] 2010;62:755-63